Two people can breathe the same polluted air, eat similar food, and carry the same DNA glitch in their cells. One develops cancer. The other does not. Scientists at the University of Cambridge have now produced the first direct evidence that inherited genetics, not just lifestyle or luck, decides which path a tumor takes.
A Controlled Test of Genetic Susceptibility
Researchers bred four strains of mice with different natural levels of liver cancer susceptibility. Together, the strains mirrored the genetic diversity seen across human populations. Each mouse received a single dose of diethylnitrosamine (DEN), a liver carcinogen found in tobacco smoke and some processed foods. The environment was identical for every animal. Only the inherited genetics varied.
The results were stark. Some strains developed aggressive tumors quickly. Others remained largely cancer free. The same chemical damage triggered different outcomes depending on the genetic background of the mouse. This gave the team direct evidence that inherited genes can steer how cancer begins and evolves after DNA damage occurs.
Why Human Studies Have Been Inconclusive
Cancer starts when DNA errors accumulate inside cells. Environmental factors like cigarette smoke and sunlight increase those errors. But most smokers never get lung cancer, and some nonsmokers do. Scientists have long suspected that inherited genetics explains part of this puzzle. Human studies have struggled to prove it because people differ in lifestyle, diet, and exposure history. Those variables make it nearly impossible to isolate the role of genetic background.
The Cambridge team, working with the University of Edinburgh and institutions across Europe and the United States, designed the mouse experiment to remove those variables. By controlling everything except the animals' genomes, they could watch how inherited differences shaped tumor evolution in real time.
What This Means for Cancer Care
The study, published in Nature, suggests that a patient's genetic background could affect how they respond to cancer treatments that damage DNA. This strengthens the argument for diagnostic and treatment strategies tailored to each individual. Doctors may eventually use inherited genetic profiles to predict not just who is at risk, but how a tumor will behave if it appears.
The research was co-led by Professor Duncan Odom, Dr. Sarah Aitken, and Professor Martin Taylor. Most experimental work took place at the Cancer Research UK Cambridge Institute. The findings offer a clear answer to a long standing question: why the same DNA damage does not affect everyone equally.
